Ocugen's OCU410ST gene therapy nears Stargardt interim readout with no rival past Phase 2
The Q3 2026 GARDian3 interim data will test a subretinal gene therapy that stands alone in advanced clinical testing for ABCA4-linked Stargardt disease.
Executive Summary
- Ocugen is heading into an interim data disclosure for its lead Stargardt disease gene therapy, the only program of its kind to reach this stage of testing.
- The interim look covers a subset of patients who have reached an early follow-up milestone, not the full trial population, so it will inform rather than settle the program's path to filing.
- The trial's completion date has been pushed back multiple times since it first registered, and enrollment grew modestly along the way, though neither shift departs from routine trial administration.
- No other gene therapy targeting the same gene has advanced past early-stage testing in this disease, leaving Ocugen's asset without a same-phase comparator to benchmark against.
The catalyst
Ocugen said an interim analysis for the GARDian3 trial (NCT05956626) is planned in the third quarter of 2026, once 24 subjects complete eight months of follow-up. The company disclosed the plan after announcing early completion of dosing in the pivotal confirmatory trial, and framed the interim look as a step ahead of topline Phase 2/3 data expected in the second quarter of 2027, which would precede a Biologics License Application filing. The trial enrolls 51 patients with genetically confirmed Stargardt disease and remains listed as Active, not recruiting. Ocugen+1Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial ResultsMar 4, 2026A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial measures
The registered primary endpoints combine safety, tracking ocular and non-ocular adverse events, with a structural efficacy measure: change from baseline in atrophic lesion size measured by Fundus Autofluorescence. The design randomizes patients to a treated arm and an untreated-control arm, with secondary endpoints covering visual acuity, quality of life, and immune response. No results have posted to the registry, and Ocugen's own January disclosure of Phase 1 GARDian1 data described a safety and tolerability profile that supported advancing to this confirmatory stage, without stating a specific effect size. NCT05956626+1A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial ResultsMar 4, 2026
Timeline and enrollment
The trial's primary completion date has moved three times since it first posted in July 2023: from October 2025 to December 2025, then to October 2025, and finally to September 2026 in July 2025. Enrollment grew from 42 to 51 patients over the same period, a 21% increase that an operational risk model flags as within the routine band for a trial of this design. The status change from Recruiting to Active, not recruiting in April 2026 reflects enrollment closing at target, consistent with a trial nearing its next data milestone rather than a sign of distress. NCT05956626A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626
The competitive field
No industry trial has reached Phase 2 or beyond targeting ABCA4 in Stargardt disease other than OCU410ST, making it the only in-class asset at this stage. The nearest mechanism peer, AAVantgarde Bio's AAVB-039, is a gene therapy targeting the same ABCA4 gene but remains in Phase 1/2 testing (NCT07161544). Two other Stargardt programs, Alkeus Pharmaceuticals' ALK-001 and Belite Bio's Tinlarebant, have reached Phase 3 but work through a different mechanism, an oral small molecule targeting retinoid metabolism rather than gene replacement. With no validated disease-modifying mechanism yet established in Stargardt disease, a lesion-growth reduction in the interim cohort that holds up in the fuller 2027 dataset would be the result that distinguishes OCU410ST from the field. NCT05956626A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.